SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors weigh strong sector growth and recent expansion news, such as its new gigawatt-scale data center project, against broader market volatility and disappointing earnings results from peers. The community is actively discussing the company's valuation, its potential as an AI infrastructure leader, and whether recent price action represents a strategic accumulation or an overextended bubble before upcoming earnings.

WORK Medical Technology Group Ltd. engages in the development of health instruments. It manufactures and sells medical devices, including endotracheal tubes, laryngeal mask airways, heat and moisture exchanging filters, disposable breathing circuits, nebulizer kits, and yankauer suction sets. The company was founded on March 1, 2022 and is headquartered in Hangzhou, China.

Work Medical Technology Group Ltd - Ordinary Shares - Class A

Work Medical Technology Group Ltd

Work Medical Technology Group is trending due to extreme volatility and massive trading volume following a low-float pump that has attracted significant community attention. Traders are actively debating whether the stock is a prime candidate for a sustained short squeeze or if it follows the pattern of previous Chinese microcap pump-and-dump cycles prone to sharp reversals.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging after disclosing that its pivotal REGAL trial has reached 78 of the 80 required events, signaling that final data unblinding is imminent. The community is buzzing with anticipation over a potential short squeeze, given the high short interest, while long-term investors highlight the transformative potential of the company's AML treatment landscape.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is seeing significant upward momentum and heavy volume following a strategic joint development agreement with Turbine-X to supply power infrastructure for AI data centers. The community is actively debating the stock's massive short interest and potential for a squeeze, while weighing the company's recent operational progress against ongoing concerns regarding manufacturing execution and capital management.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending as investors focus on its aggressive AI-driven pivot, specifically the adoption of its Qwen platform and proprietary semiconductor development, which many view as a strategic move to rival US tech giants. While some traders are expressing frustration over stagnant price action and geopolitical risks, the community remains divided between those capitalizing on the deep value discount and others who view the stock as a long-term value trap plagued by regulatory uncertainties.

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is trending as investors bet on a potential gamma and short squeeze, fueled by the company's status as a pure-play provider of radiation-hardened memory chips essential for the rapidly growing Edge AI, aerospace, and defense sectors. Community sentiment is hyper-bullish, with many traders drawing parallels to historic runs in other memory stocks while actively debating the sustainability of the current valuation amid high volatility and limited tradable float.

Wolfspeed, Inc. is an innovator of wide bandgap semiconductors, focused on silicon carbide and gallium nitride (GaN) materials and devices for power and radiofrequency (RF) applications. Its product families include silicon carbide and GaN materials, power devices and RF devices, and its products are targeted for various applications such as electric vehicles, fast charging, 5G, renewable energy and storage, and aerospace and defense. The company was founded by Calvin H. Carter Jr., John W. Palmour, F. Neal Hunter, Eric Hunter, and John Edmond in 1987 and is headquartered in Durham, NC.

Wolfspeed Inc - Ordinary Shares (New)

Wolfspeed Inc

Wolfspeed is experiencing significant volatility and trading volume as investors debate its restructuring, ongoing dilution risks, and potential for a short squeeze despite its history of bankruptcy. The community remains deeply divided, with some betting on a recovery fueled by silicon carbide demand in AI data centers, while others warn of a continued cycle of retail losses and management distrust.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is experiencing intense community focus following reports of underwhelming Q1 revenue and disappointing robotaxi performance, fueling skepticism over management's execution and the timing of recent share buybacks. Despite record year-over-year revenue growth and positive long-term partnerships with firms like Bosch and Uber, investors are expressing frustration over the stock's stagnant price action and lack of clear guidance.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is facing intense downward pressure and community backlash following the announcement of a $225 million public stock offering priced at a discount to the market price. Investors are actively debating whether this capital raise is a strategic move to fund future drone and robotics acquisitions or a sign of financial weakness, with many expressing significant frustration over dilution and questioning the integrity of management's communication regarding the company's cash position.

Kopin Corp. engages in the development, manufacture and sale of wearable technologies which include components and systems. Its portfolio includes AMLCD, LCOS displays, OLED displays, ASIC, backlights, and optical lenses. The firm uses semiconductor material technology to design, manufacture and market its component products for use in military, enterprise and consumer electronic applications, training and simulation equipment and 3D metrology equipment. The company was founded by John C.C. Fan on April 23, 1984 and is headquartered in Westborough, MA.

Kopin Corp.

Kopin Corp

Kopin Corp is seeing significant interest as investors weigh its pivot toward AI-driven optical infrastructure, specifically its MicroLED technology and partnership with Fabric AI, against its established role in defense contracts. The community is actively tracking recent analyst price target upgrades and closely monitoring the stock's volume as traders speculate on potential breakthroughs in high-speed data interconnects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$FATE Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting. Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major B cell clones up to 12 months following treatment with B cell shift towards less class-switched BCR repertoire.  
Preclinical data for FT839 demonstrate comprehensive targeting of multicellular disease across autoimmune and hematological malignancies; Preclinical data for FT836 shows effective elimination of broad range of cancers in synergy with SOC treatments. Go for moon shoot $FATE !!! $CABA  $ALLO  $ALT   $LABU

Beauty$$$Beast

Dusty McDustins

@Portfoliovalue1

Tony D. Rogers

StockTwits Web

Fate Therapeutics Inc

Cabaletta Bio Inc

Allogene Therapeutics Inc

Altimmune Inc

Direxion Daily S&P Biotech Bull 3X Shares

 Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting. Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major B cell clones up to 12 months following treatment with B cell shift towards less class-switched BCR repertoire.  
Preclinical data for FT839 demonstrate comprehensive targeting of multicellular disease across autoimmune and hematological malignancies; Preclinical data for FT836 shows effective elimination of broad range of cancers in synergy with SOC treatments. Go for moon shoot 